1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]

In development [GID-TA11571] Expected publication date: 26 March 2025

  • Project information
  • Project documents

9917-Blinatumomab-Chemotherapy-for-Acute-Lymphoblastic-Leukaemia-V1.0-JAN2024-NON-CONF.pdf (nihr.ac.uk)